Analyst Conference Summaries

Biotechnology Investor Aids

MiNK Therepeutics
INKT

conference date: August 13, 2024 @ 5:30 AM Pacific Time

MiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Up [March 25, 2023 at Seeking Alpha]

MiNK Therapeutics Undervalued Given Platform Potential [December 5, 2022 at Seeking Alpha]

MiNK Therapeutics a Bargain for Cell Therapies [June 23, 2022 at Seeking Alpha]

2024
Mink
Therapeutics
Q1 2024
Mink
Therapeutics
Q2 2024
   
May 14, 2024 Aug. 13, 2024    
2023
Mink
Therapeutics
Q1 2023
Mink
Therapeutics
Q2 2023
Mink
Therapeutics
Q3 2023
Mink
Therapeutics
Q4 2023
May 11, 2023 Aug. 10, 2023 Nov. 9, 2023 Mar. 21, 2024
2022
Mink
Therapeutics
Q1 2022
Press Release
Mink
Therapeutics
Q2 2022
Mink
Therapeutics
Q3 2022
Mink
Therapeutics
Q4 2022
May 10, 2022 Aug. 9, 2022 Nov. 3, 2022 March 21, 2023

MiNK Therapeutics (INKT) is a clinical-stage biotechnology company specializing in cell therapies for cancers and immunological diseases.

MiNK Therapeutics web site


Note: Agenus (AGEN) owns a majority of the shares of INKT common stock, per 2021 10-K

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALLO
 ALNY
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BLRX
 BLUE
 BMY
 CDTX
 CLDX
 FATE
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SANA
 SYRS
 TSVT
 VRTX
 VSTM
 WBA
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2024 William P. Meyers